system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Adolescent, Adult, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Cohort Studies, Disability Evaluation, Electric Stimulation, Evoked Potentials, Evoked Potentials, Motor, Evoked Potentials, Somatosensory, Evoked Potentials, Visual, Female, Germany, Humans, Immunologic Factors, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting, Natalizumab, Photic Stimulation, Tibial Nerve, Time Factors, Transcranial Magnetic Stimulation, Treatment Outcome, Young Adult.
user
Does natalizumab restore evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis? Context: The objective of this study was to examine the effects of natalizumab on functional parameters assessed by evoked potentials (visual [VEP], somatosensory [SEP] and motor evoked potentials [MEP]) in a cohort study in relapsing-remitting multiple sclerosis patients. EP data of 44 patients examined 12 months prior to natalizumab treatment, at the timepoint of treatment initiation and 1 year later were compared. Sum scores (VEP, MEP, SEP) were evaluated and correlated with the Expanded Disability Status Scale. Improvement of the VEP sum score was found in 33% of natalizumab-treated patients but only in 9% of the same patients prior to treatment (p = 0.041). A comparable situation was found for SEP (improvement: 32% versus 5%; worsening: 11% versus 37%; p = 0.027). For MEP no significant differences were seen (improvement: 10% versus 18%; worsening: 5% versus 29%; p = 0.60). EP recordings (VEP = SEP > MEP) have the capacity to demonstrate treatment effects of natalizumab on a functional level.
assistant
Natalizumab therapy increases the percentage of patients showing stable or even ameliorated electrophysiological parameters in the investigated functional systems. Final Decision: yes